Portada Simposios - Supplements - Haematologica

224 Haematologica (ed. esp.), volumen 85, supl. 2, octubre 2000
tional dye/drug efflux in acute myeloid leukemia by multipramenter
flow cytometry: Identification of discordant MDR1–/Efflux+ and
MDR1+/Efflux– Cases. Blood 1995; 86: 2329-2342.
39. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM et
al. Acute myeloid leukem,ia in the elderly: Assessment of multidrug resistance
(MDR1) and cytogenetics distinguishes biologic subgroups
with remarkably distinct responses to standard chemotherapy: A southwest
Oncology Group Study. Blood 1997; 89: 3323-3329.
40. Ludescher C, Eisterer W, Hilbe W, Gotwald M, Hofmann J, Zabernigg A
et al. Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic
leukemia compared to acute myeloid leukemia. Leukemia
1995; 9: 350-356.
41. Lamy T, Drenou B, Grulois I, Fardel O, Jacquelinet C, Goasguen J et al.
Multidrug ressitance (MDR) activity in acute leukemia determined by
rhodamine 123 efflux assay. Leukemia 1995; 9: 1549-1555.
42. Martínez A, San Miguel JF, Valverde B, Bárez A, Moro MJ, García-Marcos
MA et al. Functional expresion of MDR-1 in acute myloid leukemia:
correlation with the clinical-biological, immunophenotypical, and
prognostic disease characteristics. Ann Hematol 1997; 75: 81-86.
43. San Miguel JF, Martínez A, Macedo A, Vidriales MB, López-Berges C,
González M et al. Immunophenotyping investigation of MRD is a useful
approach for predicting relapse in AML patients. Blood 1997; 90:
2465-2470
44. Langabeer SE, Grinwade D, Walker H et al. A study to determine whether
trisomy 8, deleted 9q and trisomy 22 are markers of cryptic rearrangements
of PML/RAR, AML1/ETO and CBFB/MYH11 respectively
in acute myeloid leukaemia. Br J Haematol 1998; 101: 338-340.
45. Beverloo HB, Van Drunen E, Smit B, Slater R. Identification of new chromosomal
aberrations aberrations in acute leukemia using spectral
karyotyping. Blood 1999; Supl. 1: 494a.
46. Mrozek K, Heinonen K, De la Chapelle A, Bloomfield CD. Clinical significance
of cytogenetics in acute myeloid leukemia. Semin Oncol 1997;
24:17-31.
47. Byrd JC, Weiss RB, Arthur DC et al. Extramedullary leukemia adversely
affects hematologic complete remission rate and overall survival in patients
with t(8;21)(q22;q22): results from Cancer and Leukemia Group
B 8461. J Clin Oncol 1997; 15: 466-475.
48. Dastugue N, Payen C, Lafage-Pochitaloff M et al. Prognostic significance
of karyotpye in de novo adult acute myeloid leukemia. Leukemia
1995; 9: 1491-1498.
49. Grinwade D, Walker H, Oliver F et al. The importance of diagnostic cytogenetics
on outcome in AML: Analysis of 1612 patients entered into
the MRC AML trial. Blood 1998; 92: 2322-2333.
50. Slovak ML, Kopecky KJ, Cassileth PA et al. Karyotypic analysis predicts
outcome of pre- and post-remission therapy in adult acute myeloid leukemia
(AML): A SWOG/ECOG intergroup study. Blood 1998; 76:
2594.
51. Byrd JC, Lawrence D, Arthur DC. Patients with isolate trisomy 8 in acute
myeloid leukemia are not cured with cytarabine-based chemotherapy:
Results from Cancer and Leukemia Group B 8461. Clin Cancer
Res 1998; 4: 1235-1241.
52. Schoch C, Haase D, Fonatsch C et al. The significance of trisomy 8 in de
novo acute myeloid leukaemia: the accompaning chromosome aberrations
determine the prognosis. Br J Haematol 1997; 605-611.
53. Mrozek K, Heinonen K, Lawrence D et al. Adult patients with de novo
acute myeloid leukemia and t(9;11)(p22;q23) have a superior outcome
to patients with other translocations involving band 11q23: a Cancer
and Leukemia Group B Study. Blood 1997; 90: 4532-4538.
54. Estey EH, Pierce S, Keating MJ. Identification of a group of AML/MDS
patients with a relative favourable prognosis who have chromosome
5 and/ 7 abnormalities. Haematologica 2000; 85: 246-249.
55. Martínez-Climent JA, Lane NA, Rubin CM et al. Clinical and prognostic
significance of chromosomal abnormalities in childhood acute myeloid
leukemia de novo. Leukemia 1995; 9: 95-101.
56. Raimondi SC, Chang MN, Ravindranath Y et al. Chromosomal abnormalities
in 478 children with acute myeloid leukemia: clinical characteristics
and treatment outcome in a cooperative pediatric oncology
group study-POG 8821. Blood 1999; 94: 3707-3716.
57. Pui CH, Raimondi SC, Srivastava DK et al. Prognostic factors in infants
with acute myeloid leukemia. Leukemia 2000; 14: 684-687.
58. Bloomfield CD, Lawrence D, Byrd JC et al. Frequency of prolonged remission
duration after high-dose cytarabine intensification in acute
myeloid leukemia, varies by cytogenetic subtype. Cancer Res 1998; 58:
4173-4179.
59. Wheatley K, Burnett AK, Goldstone AH et al. A simple, robust, validated
and highly predictive index for the determination of risk-directed
therapy in acute myeloid lekaemia derived from the MRC AML 10 trial.
Br J Haematol 1999; 107: 69-79.
60. Ferrant A, Labopin M, Frassoni F et al. Karyotype in acute myeloblastic
leukemia: prognostic significance for bone marrow transplantation
in first remission: a European Group for Blood and Marrow transplantation
study. Blood 1997; 90: 2931-2938.
61. San Miguel JF, González M, Orfao A. Detection of Minimal Residual disease
in Myeloid Malignancies. Textbook of Malignant Haematology
1999; 871-891.
62. San Miguel JF, Van Dongen JJM. Methods of detection of minimal residual
disease. Acute Leukemias VI Prognostic Factors and Treatment
Strategies. Büchner et al, eds. Berlin: Springer Verlag, 1997;
307-312.
63. Macedo A, Orfao A, Vidriales MB, López Berges MC, González M, Caballero
MD et al Characterization of aberrant phenotypes in acute myeloblastic
leukemia. Ann Hematol 1995; 70: 189-194.
64. Sievers EL, Loken MR. Detection of minimal residual disease in acute
myelogenous leukemia. J Pediatr Hematol Oncol 1995; 17: 123-33.
65. Macedo A, Orfao A, Gonzalez M, Vidriales MB, López-Berges MC,
Martínez A et al. Immunological detection of blast cell subpopulations
in acute myeloblastic leukemia at diagnosis: implications for minimal
residual disease studies. Leukemia 1995; 9: 993-998.
66. Campana D, Coustan-Smith E, Janossy G. The immunologic detection
of minimal residual disease in acute leukemia. Blood 1990; 76:
163-171.
67. Adriaansen HJ, Jacobs BC, Kappers-Klunne MC, Hählen K, Hooijkaas
H, van Dongen JJM. Detection of residual disease in AML patients by
use of double immunological marker analysis for terminal deoxynucleotidyl
transferase and myeloid markers. Leukemia 1993; 7: 472-481.
68. Campana D, Pui CH. Detection of minimal residual disease in acute
leukemia: methodologic advances and clinical significance. Blood
1995; 85: 1416-1434.
69. Reading CL, Estey EH, Huh YO, Claxton DF, Sánchez G, Terstappen
LWMM et al. Expression of unusual immunophenotype combinations
in acute myelogenous leukemia. Blood 1993; 81: 3083-3090.
70. Van Dongen JJM, Macintyre EA, Delabesse E, Gabert JA, Biondi A,
Cazzaniga G et al. Standardized RT-PCR analysis of fusion gene transcripts
from chromosome aberrations in acute leukaemia for detection
of minimal residual disease. Report of the BIOMED-1 Concerted Action
investigation of minimal residual disease in acute leukemia. Leukemia
1999; 13: 1901-1928.
71. Sanchez I, San Miguel JF, Corral J, Martin C, Perez R, Gonzalez M et al.
Gene rearrangement in acute non lymphoblastic leukemia. Correlation
with morphological and immunophenotypic characteristics of blast
cells. Br J Haematol 1995; 89: 104-109
72. Van Dongen JJM, Szcepanski T, De Bruijn MAC, Van den Beemd MW,
de Bruin-Versteeg S, Wijkhuijs JM et al. Detection of minimal residual
disease in acute leukemia patients. Cytokines Mol Ther 1996; 2:
121-133.
73. Bolufer P, Barragán E, Sanz MA, Martín G, Borstein R, Colomer D et
al. Preliminary experience in external quality control of RT-PCR
PML-RARa detection in promyelocytic leukemia. Leukemia 1998; 12:
2024-2028.
74. Lo Coco F, Diverio D, Pandolfi PP, Biondi A, Rossi V, Avvisati G et al.
Molecular evaluation of residual disease as a predictor of relapse in
acute promyelocytic leukemia. Lancet 1992; 340: 1437-1438.
75. Guerrasio A, Rosso C, Martinelli G, Lo Coco F, Pampinella M, Santoro
A et al. Polyclonal haemopoieses associated with long-term persistence
of the AML1/ETO transcript in patients with FAB M2 acute myeloid
leukaemia in continuous clinical remission. Br J Haematol 1995; 90:
364-368.
76. Elmaagacli AH, Beelen DW, Kroll M, Trzensky S, Stein C, Schaefer UW.
Detection of CBF/MYH11 fusion transcripts in patients with inv(16)
acute myeloid leukemia after allogeneic bone marrow or peripheral blood
progenitor cell transplantation. Bone Marrow Transplant 1998;
21: 159-166.
77. Martín G, Barragán E, Bolufer P, Chillón C, García-Sanz R, Gómez T et
al. Relevance of presenting white blood cell count and kinetics of molecular
remission in the prognosis of acute myeloid leukemia with
CBF/MYH11 rearrangement Hematologica; 2000 (en prensa).
78. Lo Coco F, Diverio D, Falini B, Biondi A, Nervi C, Pelicci PG. Genetic
diagnosis and molecular moniitoring in the manegement of acute
promyelocytic leukemia. Blood 1999; 94: 12-22.
79. Satake N, Maseki N, Kozu T, Sakashita A, Kobayashi H, Sakurai M et al.
Disapareamce of AML1-METG8 (ETO) fusion transcript in acute myeloid
leukemia patients with t(8;21) in long term remission. Br J Haematol
1995; 91: 892-898.
80. Elmaagacli AH, Beelen DW, Kroll M, Trzensky S, Stein C, Schaefer UW.
Detection of CBF/MYH11 fusion transcripts in patients with inv(16)
acute myeloid leukemia after allogeneic bone marrow or peripheral blood
progenitor cell transplantation. Bone Marrow Transplant 1998;
21: 159-166.
81. Morschhauser F, Cayuela JM, Martini S, Baruchel A, Rousselot P, Socié
G et al. Evaluation of minimal residual disease using reverse-transcription
polymerase chain reaction in t(8;21) acute myeloid leukemia: a
multicenter study of 51 patients. J Clin Oncol 2000; 18: 788-794.
82. Tobal K, Yin AL. Monitoring of minimal residual disease by quantitative
reverse transcriptase-poymerase chain reaction for AML1-MTG8 transcripts
in AML-M2 with t(8;21). Blood 1996; 88: 3704-3709.
83. Evans PAS, Short MA, Jack AS, Norfolk DR, Child JA, Shiach CR et al.
Detection and quantification of the CBFbeta/MYH11 fusion transcript
associated whit the inv(16) in presentation and follow-up samples from
patients with AML. Leukemia 1997; 11: 364-369.
84. Gibson UEM, Heid CA, Williams PM. A novel method for Real Time
quantitative RT-PCR. Genome Res 1996; 6: 995-1001.
85. Marcucci G, Livak KJ, Bi W, Strout MP, Bloomfield CD, Caligiuri MA.
Detection of minimal residual disease in patients with AML/ETO-associated
acute myeloid leukemia using a novel quantitative reverse transcription
polymerase chain reaction assay. Leukemia 1998; 12:
1482-1489.
86. Cassinat B, Zassadowski, F, Balitrand N, Barbey C, Rain JD, Feneax P
et al. Quantitation of minimal residual disease in acute promyelocytic
leukemia patients with t(15;17) translocation using real-time RT-PCR.
Leukemia 2000; 14: 324-328.
87. Grimwade D, Diverio D, Harrison G, Wheatley K, Rodgers J, Lo Coco F
et al. Detection of minimal residual disease (MRD) in APL by
“Real-Time” RT-PCR: analysis of cases entered into the UK MRC ATRA
trial. Blood 1999; 94: 10 (Supl. 1): 625a.